LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$15.70 USD
-0.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
LENZ 15.70 -0.02(-0.13%)
Will LENZ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for LENZ
Lenz Therapeutics management to meet with Piper Sandler
LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for LENZ Therapeutics Amidst Strong Clinical Progress and Market Potential
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)